Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results.

Systemically disseminated cutaneous T-cell lymphoma is generally resistant to chemotherapy and radiotherapy. We tested a treatment involving the extracorporeal photoactivation of biologically inert methoxsalen (8-methoxypsoralen) by ultraviolet A energy to a form that covalently cross-links DNA. After oral administration of methoxsalen, a lymphocyte-enriched blood fraction was exposed to ultraviolet A (1 to 2 J per square centimeter) and then returned to the patient. The combination of ultraviolet A and methoxsalen caused an 88 +/- 5 percent loss of viability of target lymphocytes, whereas the drug alone was inactive. Twenty-seven of 37 patients with otherwise resistant cutaneous T-cell lymphoma responded to the treatment, with an average 64 percent decrease in cutaneous involvement after 22 +/- 10 weeks (mean +/- SD). The responding group included 8 of 10 patients with lymph-node involvement, 24 of 29 with exfoliative erythroderma, and 20 of 28 whose disease was resistant to standard chemotherapy. Side effects that often occur with standard chemotherapy, such as bone marrow suppression, gastrointestinal erosions, and hair loss, did not occur. Although the mechanism of the beneficial effect is uncertain, an immune reaction to the infused damaged cells may have restricted the activity of the abnormal T cells. This preliminary study suggests that extracorporeal photochemotherapy is a promising treatment for widespread cutaneous T-cell lymphoma.

[1]  J. Parrish,et al.  Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. , 1974, The New England journal of medicine.

[2]  P. Schein,et al.  Successful management of the Sézary syndrome. Mobilization and removal of extravascular neoplastic T cells by leukapheresis. , 1974, The New England journal of medicine.

[3]  A. Ahmed,et al.  Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. , 1975, Annals of internal medicine.

[4]  J. Parrish,et al.  Oral methoxsalen photochemotherapy of mycosis fungoides , 1976, Cancer.

[5]  M. Pathak,et al.  Molecular and genetic basis of furocoumarin reactions. , 1976, Mutation research.

[6]  K. Lennert.  [Classification and morphology of non-Hodgkin's lymphomas]. , 1976, Hamatologie und Bluttransfusion.

[7]  C. Puglisi,et al.  Determination of 8-Methoxypsoralen, A Photoactive Compound, in Blood by High Pressure Liquid Chromatography , 1977 .

[8]  J. Parrish,et al.  Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. , 1977, The Journal of investigative dermatology.

[9]  D. Warburton,et al.  Karyotype studies of cutaneous T cell lymphoma: evidence for clonal origin. , 1979, The Journal of investigative dermatology.

[10]  P. Song,et al.  PHOTOCHEMISTRY AND PHOTOBIOLOGY OF PSORALENS , 1979, Photochemistry and photobiology.

[11]  I. Cohen,et al.  Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein , 1981, Nature.

[12]  R. Winkelmann,et al.  Leukapheresis in the treatment of Sézary syndrome. , 1981, Journal of the American Academy of Dermatology.

[13]  S. Morrison,et al.  Diagnosis of cutaneous T cell lymphoma by use of monoclonal antibodies reactive with tumor-associated antigens. , 1982, The Journal of clinical investigation.

[14]  P. Nowell,et al.  Clonal Characteristics of Cutaneous T Cell Lymphomas: Cytogenetic Evidence from Blood, Lymph Nodes, and Skin , 1982 .

[15]  J. Parrish,et al.  Abnormal lymphocyte function following long‐term PUVA therapy for psoriasis , 1983, The British journal of dermatology.

[16]  I. Cohen,et al.  Lines of T lymphocytes induce or vaccinate against autoimmune arthritis. , 1983, Science.

[17]  H. Hönigsmann,et al.  Photochemotherapy for cutaneous T cell lymphoma. A follow-up study. , 1984, Journal of the American Academy of Dermatology.

[18]  D. Byar,et al.  Clinical staging for cutaneous T-cell lymphoma. , 1984, Annals of internal medicine.

[19]  R. Stern,et al.  Cutaneous squamous-cell carcinoma in patients treated with PUVA. , 1984, The New England journal of medicine.

[20]  R. Warnke,et al.  Clonal rearrangements of T-cell receptor genes in mycosis fungoides and dermatopathic lymphadenopathy. , 1985, The New England journal of medicine.

[21]  E. Pfendt,et al.  A murine monoclonal antibody (VM-1) against human basal cells inhibits the growth of human keratinocytes in culture. , 1985, The Journal of investigative dermatology.

[22]  C. Cantor,et al.  Comparison of Synthetic Psoralen Derivatives and 8‐MOP in the Inhibition of Lymphocyte Proliferation a , 1985, Annals of the New York Academy of Sciences.

[23]  P. Nowell,et al.  Diagnostic and prognostic significance of Sézary cells in peripheral blood smears from patients with cutaneous T cell lymphoma. , 1985, Blood.

[24]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[25]  F. Gasparro,et al.  Phototherapy and photopharmacology. , 1985, The Yale journal of biology and medicine.

[26]  Ilan R. Kirsch,et al.  T-cell receptor gene rearrangements as clinical markers of human T-cell lymphomas. , 1985, The New England journal of medicine.

[27]  F. Gasparro,et al.  Monoclonal antibodies to DNA modified by 8-methoxypsoralen and ultraviolet A light. , 1985, Nucleic acids research.

[28]  H. Bayley,et al.  The Delivery of Phototoxic Drugs to Selected Cells a , 1985, Annals of the New York Academy of Sciences.

[29]  F. Gasparro,et al.  Receptor-mediated photo-cytotoxicity: synthesis of a photoactivatable psoralen derivative conjugated to insulin. , 1986, Biochemical and Biophysical Research Communications - BBRC.